Chemical Synthesis and Optimization Facility for Advancing Non-Hormonal Contraceptive and Reproductive Health Product Development
This grant opportunity from NICHD provides support for preclinical studies to help develop new contraceptive and reproductive health therapies. The aim is to advance promising candidates to the stage where they can be tested under regulatory approvals like Investigational Device Exemption (IDE) or Investigational New Drug (IND).
The NICHD's facility offers preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies. The goal is to enable a preclinical candidate for IND/IDE study(ies) that offers a safe therapeutic option in contraception and reproductive healt…
Source
Eligibility
- Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Required registrations (must be completed before submission; can take 6+ weeks): SAM (active; renew at least annually; CAGE code for domestic organizations), NCAGE code for foreign organizations (to re…
Dates
Supporting links
Similar opportunities
-
Contraceptive Development Research Center
-
Accelerating Innovative Drug and Device Therapies Translation from Discovery to Early Human Studies
-
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required)
-
Notice of Funding Opportunity for Rare Disease Therapeutic Development
-
Notice of Funding Opportunity for Precision Medicine in Pregnant and Lactating Women and Children